Correlation between serum gastrin and cellular proliferation in Barrett’s esophagus

Green, Daniel A.; Mlynarczyk, Carrie M.; Vaccaro, Benjamin J.; Capiak, Kristina M.; Quante, Michael; Lightdale, Charles J.; Abrams, Julian A.

doi:10.1177/1756283x10392444

Cited by 9 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study investigating colorectal cancer risk found no such association . In BO, a recent in vivo and vitro study found no association between length of oesophageal metaplasia and gastrin level, whereas two other studies found a significant correlation between gastrin and the risk of dysplasia and OAC …”

Section: Discussionmentioning

confidence: 91%

Proton pump inhibitor use may not prevent high‐grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients

Hvid-Jensen

Pedersen

Funch‐Jensen

et al. 2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

Proton pump inhibitor use may not prevent high‐grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients

Hvid-Jensen

Pedersen

Funch‐Jensen

et al. 2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…However, clinical studies addressing this issue are scarce. A few recent clinical studies support the pro-carcinogenic role of tissue gastrin and SG in the development of gastric and extragastric tumors, respectively (20)(21)(22)(23)(24). The origin of gastrin for these effects might be either serum-associated endocrine gastrin or autocrine gastrin produced by tumor cells.…”

Section: Discussionmentioning

confidence: 98%

Serum gastrin levels in different stages of distal gastric carcinogenesis: Is there a role for serum gastrin in tumor growth?

Kim

Jung

Kim

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: Elevated levels of serum gastrin (SG) have been associated with tumorigenic effects in a number of gastrointestinal cancers. We decided to investigate the relationship between SG and gastric epithelial lesions. Materials and Methods: A total of 90 patients with gastric epithelial lesions (hyperplastic polyp, 12; adenoma, 41; early gastric cancer, 29; advanced gastric cancer, 8) were enrolled as the case group and 79 patients without epithelial lesions were enrolled as the control group. Results: Serum gastrin levels were significantly different between the case and control groups (p<0.001). A high SG level (>80 pg/mL), intestinal metaplasia, and a pepsinogen I/II ratio <3 were independently associated with an increased risk of epithelial lesions (odds ratio: 14.6, 9.4, and 4.1, respectively, p<0.05). SG levels in case subjects showed a unimodal distribution pattern as the disease progressed. The mean SG level was highest in those with hyperplastic polyps and then decreased significantly to the control level in the gastric cancer group. Higher SG levels in each disease category were not associated with increased tumor size, synchronicity, invasiveness, presence of lymph node metastasis, or a higher cellular proliferation index (p>0.05). Conclusion: An increased SG level was an independent and potent risk factor for gastric epithelial lesions. However, it does not seem to relate with distal gastric tumor growth. Serial decreases in SG levels should be considered a warning sign in index hypergastrinemic patients with no prior Helicobacter pylori eradication.

show abstract

“…In vitro studies have revealed that gastrin has a pro-proliferative effect on Barrett’s epithelium [39]. A potential causal effect of gastrin on neoplastic progression in human BE has been supported by one study showing that serum gastrin levels were significantly correlated with cellular proliferation in nondysplastic BE patients on PPI therapy [40]. Moreover, it is well-known that reflux symptoms correlate poorly with the actual amount of refluxate in patients with GERD, and that BE may even make patients hyposensitive to acid refluxate [41].…”

Section: Discussionmentioning

confidence: 99%

Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus: A Systematic Review and Meta-Analysis

Sun

Hong

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

ObjectivesProton pump inhibitors (PPIs) have been used for treatment of Barrett's esophagus (BE) for many years. However, the connection between PPIs and esophageal adenocarcinoma (EAC) in patients with BE has still been controversial. The current systematic review and meta-analysis was designed to evaluate the association between PPIs and the risk of EAC or high-grade dysplasia (HGD) in patients with BE.MethodsA systematic literature search of studies reporting the association between PPIs and the risk of EAC and/or HGD in patients with BE was conducted in PubMed, Embase, Web of Science and the Cochrane Library. Next, literature was screened using previously established criteria and relevant data were extracted from included studies. Finally, the software program Review Manage 5.2 was applied to aggregate data and analyze the results.ResultsNine observational studies, comprising five cohort and four case-control studies (including a total of 5712 patients with BE), were identified. Upon meta-analysis, PPIs were found to have no association with the risk of EAC and/or HGD in patients with BE (unadjusted OR 0.43, 95% CI 0.17–1.08). Analysis for duration response relationship revealed no significant trend toward protection against EAC or HGD with PPIs usage for >2~3 years (one study using 7-year cutoff) when compared to usage for shorter time periods (PPIs usage >2~3 years vs. <2~3 years: OR 0.91 (95% CI 0.25–3.31) vs. 0.91 (0.40–2.07)).There also was considerable heterogeneity between studies.ConclusionNo dysplasia- or cancer-protective effects of PPIs usage in patients with BE were identified by our analysis. Therefore, we conclude that clinicians who discuss the potential chemopreventive effects of PPIs with their patients, should be aware that such an effect, if exists, has not been proven with statistical significance.

show abstract

Correlation between serum gastrin and cellular proliferation in Barrett’s esophagus

Cited by 9 publications

References 24 publications

Proton pump inhibitor use may not prevent high‐grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients

Proton pump inhibitor use may not prevent high‐grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients

Serum gastrin levels in different stages of distal gastric carcinogenesis: Is there a role for serum gastrin in tumor growth?

Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About